X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs MERCK LTD - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. MERCK LTD FRESENIUS KABI ONCO./
MERCK LTD
 
P/E (TTM) x 22.1 26.8 82.5% View Chart
P/BV x 3.1 3.0 103.7% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 FRESENIUS KABI ONCO.   MERCK LTD
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
MERCK LTD
Dec-16
FRESENIUS KABI ONCO./
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1761,060 16.6%   
Low Rs79623 12.6%   
Sales per share (Unadj.) Rs37.7632.4 6.0%  
Earnings per share (Unadj.) Rs5.145.7 11.1%  
Cash flow per share (Unadj.) Rs6.762.3 10.8%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs42.5388.8 10.9%  
Shares outstanding (eoy) m158.2316.60 953.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 253.8%   
Avg P/E ratio x25.018.4 135.7%  
P/CF ratio (eoy) x18.913.5 140.2%  
Price / Book Value ratio x3.02.2 138.2%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m20,13513,969 144.1%   
No. of employees `0001.21.6 72.8%   
Total wages/salary Rs m7031,487 47.3%   
Avg. sales/employee Rs Th5,176.26,631.9 78.1%   
Avg. wages/employee Rs Th610.4939.2 65.0%   
Avg. net profit/employee Rs Th699.6479.4 145.9%   
INCOME DATA
Net Sales Rs m5,96310,498 56.8%  
Other income Rs m18242 7.4%   
Total revenues Rs m5,98110,741 55.7%   
Gross profit Rs m1,4301,135 126.0%  
Depreciation Rs m258276 93.6%   
Interest Rs m-260-   
Profit before tax Rs m1,2161,102 110.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342343 99.7%   
Profit after tax Rs m806759 106.2%  
Gross profit margin %24.010.8 221.8%  
Effective tax rate %28.131.1 90.3%   
Net profit margin %13.57.2 187.0%  
BALANCE SHEET DATA
Current assets Rs m5,1026,410 79.6%   
Current liabilities Rs m2,3858,828 27.0%   
Net working cap to sales %45.6-23.0 -197.7%  
Current ratio x2.10.7 294.6%  
Inventory Days Days15058 260.1%  
Debtors Days Days11338 295.1%  
Net fixed assets Rs m5,1481,406 366.0%   
Share capital Rs m158166 95.3%   
"Free" reserves Rs m6,5566,286 104.3%   
Net worth Rs m6,7326,455 104.3%   
Long term debt Rs m9520-   
Total assets Rs m10,3888,828 117.7%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.2 48.3%   
Return on assets %7.58.6 87.3%  
Return on equity %12.011.8 101.8%  
Return on capital %14.617.1 85.5%  
Exports to sales %74.58.3 899.2%   
Imports to sales %24.821.0 117.7%   
Exports (fob) Rs m4,441869 510.8%   
Imports (cif) Rs m1,4772,209 66.9%   
Fx inflow Rs m5,298959 552.5%   
Fx outflow Rs m1,7722,612 67.8%   
Net fx Rs m3,525-1,653 -213.2%   
CASH FLOW
From Operations Rs m1,2741,070 119.0%  
From Investments Rs m-1,204-750 160.6%  
From Financial Activity Rs m-196-150 130.9%  
Net Cashflow Rs m-126171 -73.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 51.8 156.4%  
Indian inst/Mut Fund % 0.3 18.2 1.6%  
FIIs % 9.6 1.0 960.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 29.1 31.3%  
Shareholders   42,599 28,591 149.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS